These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
968 related articles for article (PubMed ID: 35478046)
21. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957 [TBL] [Abstract][Full Text] [Related]
23. Fracture risk following intermission of osteoporosis therapy. Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S; Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404 [TBL] [Abstract][Full Text] [Related]
24. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589 [TBL] [Abstract][Full Text] [Related]
25. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024. Cosman F; Lewiecki EM; Eastell R; Ebeling PR; Jan De Beur S; Langdahl B; Rhee Y; Fuleihan GE; Kiel DP; Schousboe JT; Borges JL; Cheung AM; Diez-Perez A; Hadji P; Tanaka S; Thomasius F; Xia W; Cummings SR J Bone Miner Res; 2024 Sep; 39(10):1393-1405. PubMed ID: 39073912 [TBL] [Abstract][Full Text] [Related]
26. Use of calcium supplements, vitamin D supplements and specific osteoporosis drugs among French women aged 75-85 years: patterns of use and associated factors. Castro-Lionard K; Dargent-Molina P; Fermanian C; Gonthier R; Cassou B Drugs Aging; 2013 Dec; 30(12):1029-38. PubMed ID: 24114665 [TBL] [Abstract][Full Text] [Related]
27. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929 [TBL] [Abstract][Full Text] [Related]
28. Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures. Aguado-Maestro I; Panteli M; García-Alonso M; Bañuelos-Díaz A; Giannoudis PV Injury; 2017 Dec; 48 Suppl 7():S27-S33. PubMed ID: 28851521 [TBL] [Abstract][Full Text] [Related]
29. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C; JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157 [TBL] [Abstract][Full Text] [Related]
30. Low rate of densitometric diagnosis and treatment in patients with severe osteoporosis in Colombia. Fernández-Ávila DG; Rincón-Riaño DN; Pinzón DF; Gutiérrez Dávila JM Arch Osteoporos; 2019 Sep; 14(1):95. PubMed ID: 31486920 [TBL] [Abstract][Full Text] [Related]
32. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials. Deardorff WJ; Cenzer I; Nguyen B; Lee SJ JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231 [TBL] [Abstract][Full Text] [Related]
33. Denosumab versus Bisphosphonates for Reducing Fractures in Postmenopausal Women with Osteoporosis: A Meta-Analysis. Thal KA; Nudy M; Moser EM; Foy AJ J Am Board Fam Med; 2023 Feb; 36(1):175-185. PubMed ID: 36653115 [TBL] [Abstract][Full Text] [Related]
34. Clinical Practice. Postmenopausal Osteoporosis. Black DM; Rosen CJ N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873 [TBL] [Abstract][Full Text] [Related]
35. Secondary prevention of osteoporosis: Calcium, Vitamin D and bisphosphonate prescribing following distal radial fracture. Talbot JC; Elener C; Praveen P; Shaw DL Injury; 2007 Nov; 38(11):1236-40. PubMed ID: 17572417 [TBL] [Abstract][Full Text] [Related]
36. Osteoporosis: trials and tribulations. Seeman E Am J Med; 1997 Aug; 103(2A):74S-87S; discussion 87S-89S. PubMed ID: 9302899 [TBL] [Abstract][Full Text] [Related]
37. Medical treatment of osteoporosis. Palacios S Climacteric; 2022 Feb; 25(1):43-49. PubMed ID: 34382489 [TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials. Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908 [TBL] [Abstract][Full Text] [Related]
39. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML; Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857 [TBL] [Abstract][Full Text] [Related]